Scholarlink

<p>Various risk classification systems (RCSs) are used globally to stratify newly diagnosed patients with prostate cancer (PCa) into prognostic groups. This study evaluated the predictive value of risk groups (low-, intermediate-, and high-risk) within four RCSs (EAU, NCCN, CPG, and CAPRA) for detecting metastases on primary PSMA-PET/CT. Metastases were observed in 35% (931/2.630) of patients. Prevalence among intermediate- and high-risk groups ranged from 12&#xa0;to 46%. Two RCSs subdivided these groups: metastatic disease was found in 5.8%, 13%, 22%, and 62% for favorable intermediate-, unfavorable intermediate-, high-, and very-high-risk PCa (NCCN); and 6.9%, 13%, 21%, and 60% for the corresponding CPG groups. This study highlights the importance of detailed risk stratification, and PSMA-PET/CT for primary staging should be reserved for patients with unfavorable intermediate-risk prostate cancer or higher.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Een vergelijking van wereldwijd toegepaste prognostische risicoclassificatiesystemen en de prevalentie van metastasen op PSMA PET/CT bij patiënten met nieuw gediagnosticeerde prostaatkanker

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月1日

查看全文
  • Wietske I. Luining,
  • Tessa R. de Weijer,
  • Liselotte M. S. Boevé,
  • Marinus J. Hagens,
  • Dennie Meijer,
  • Rosemarijn H. Ettema,
  • Remco J. J. Knol,
  • Ton A. Roeleveld,
  • Sandra Srbljin,
  • Saskia Weltings,
  • José C. C. Koppes,
  • Reindert J. A. van Moorselaar,
  • Pim J. van Leeuwen,
  • Matthijs C. F. Cysouw,
  • Daniela E. Oprea-Lager,
  • André N. Vis

摘要

Various risk classification systems (RCSs) are used globally to stratify newly diagnosed patients with prostate cancer (PCa) into prognostic groups. This study evaluated the predictive value of risk groups (low-, intermediate-, and high-risk) within four RCSs (EAU, NCCN, CPG, and CAPRA) for detecting metastases on primary PSMA-PET/CT. Metastases were observed in 35% (931/2.630) of patients. Prevalence among intermediate- and high-risk groups ranged from 12 to 46%. Two RCSs subdivided these groups: metastatic disease was found in 5.8%, 13%, 22%, and 62% for favorable intermediate-, unfavorable intermediate-, high-, and very-high-risk PCa (NCCN); and 6.9%, 13%, 21%, and 60% for the corresponding CPG groups. This study highlights the importance of detailed risk stratification, and PSMA-PET/CT for primary staging should be reserved for patients with unfavorable intermediate-risk prostate cancer or higher.